Incyte, Steadymed, United Therapeutics Stocks Moving Today

Three stocks making big moves on the charts today are biotechs Incyte, Steadymed, United Therapeutics

Apr 3, 2017 at 2:37 PM
facebook X logo linkedin

U.S. stocks are starting the second quarter off on a low note. Among specific equities on the move this afternoon are biotech stocks Incyte Corporation (NASDAQ:INCY), Steadymed Ltd (NASDAQ:STDY), and United Therapeutics Corporation (NASDAQ:UTHR). Here's a quick look at what's moving shares of INCY, STDY, and UTHR.

Incyte Stock Comes in as Top SPX Performer 

INCY is the top-performing S&P 500 Index (SPX) stock today, thanks to news the company is advancing its cancer drug program with Bristol-Myers Squibb Co (NYSE:BMY). Incyte Corporation shares were last seen 4.1% higher at $139.21, but topped out just short of their 20-day moving average. Still, INCY stock has roughly doubled in value over the past year, which likely explains why every single analyst covering the shares rates them a "buy" or "strong buy." Just this morning, in fact, BMO and Leerink raised their respective price targets to $170 and $141 -- with the former mark representing record-high territory. 

Patent Ruling Sends Steadymed Stock Soaring

A favorable patent ruling over United Therapeutics has STDY stock up 31.8% at $7.65, making it one of the top Nasdaq performers today, with the shares earlier touching an annual high of $9.70. Steadymed Ltd stock has been soaring up the charts in 2017, roughly tripling in value. H.C. Wainwright is expecting much more upside, too, boosting its price target by 50% -- to $15 from $10, in uncharted territory. We'll see if STDY's huge moves on the charts entice additional brokerage firms to jump aboard, since only two analysts are officially tracking the stock at the moment. 

United Therapeutics Set to Breach 200-Day Moving Average

Meanwhile, the same patent news -- as well as regulatory delays of the company's RemoSynch device -- has UTHR down 8.9% today to trade at $123.39, putting the shares on pace for their first close below their 200-day moving average since early November. The stock has been trending lower since touching an annual high of $169.89 in late February, and most analysts are bearish, even though United Therapeutics Corporation stock is still slightly higher on a year-over-year basis. Specifically, 70% of brokerage firms tracking UTHR stock say it's a "hold" or worse. Meanwhile, short sellers are likely pleased; short interest represents nearly two weeks' of pent-up buying power, at UTHR's average daily trading volume. 

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI